

सं. / No. 50014/03/2020-CDN

भारत सरकार / Government of India

रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers

औषध विभाग / Department of Pharmaceuticals

शास्त्री भवन, नई दिल्ली / Shastri Bhawan, New Delhi

Dated: 14th March, 2023

Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of February, 2023-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of February, 2023 for information.



(Shamim Uddin Ansari)

Under Secretary to the Govt. of India

Tel. 011-23387920

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. Sr. PPS to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

**Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals**

1. Important policy decisions taken and major achievements during the month of February 2023:

A. COVID Drug Management and Monitoring

As part of the COVID drug management monitoring work, availability and stock of drugs related to COVID management was reviewed in the meeting of the COVID Drug Management Committee chaired by Secretary, DoP on 23.2.2023. Committee was apprised of the results of four market surveys conducted by Price Monitoring and Resource Units (PMRUs) in 18 States/UTs during February, 2023 for COVID management drugs and six medical devices as well as surveys conducted by DCGI. It was informed that current situation does not indicate any undesirable change in status.

B. National Pharmaceutical Pricing Authority (NPPA):

(i) Achievements:

- (a) Retail prices of 92 new drugs have been fixed during the month of February, 2023 bringing cumulative figure to 2274 till February, 2023.
- (b) Ceiling price of 137 scheduled formulations have been fixed during the month of February, 2023 bringing cumulative figure to 481 till February, 2023.
- (c) On the basis of Monitoring & Enforcement activities, 30 Preliminary Notices (PN) and 01 Show Cause Notice (SCN) was issued.
- (d) NPPA through Price Monitoring and Resource Units (PMRUs) in the States/ UTs have conducted four (4) market research analysis in February, 2023 to assess the availability of COVID Management Drugs in the States/ UTs.
- (e) An interactive webinar with PMRUs was organised by NPPA on 27.02.2023 on 'Activities of PMRUs' to provide guidance on various activities to be performed by PMRUs. The PMRUs in the States/ UTs have actively participated in the webinar.
- (f) A New PMRU has been set up in the State of Meghalaya in the month of February - 2023. With this Twenty-Six (26) Price Monitoring and Resource Unit (PMRU) have been set up in the States till date, viz., Kerala, Gujarat, Odisha, Rajasthan, Punjab, Haryana, Tripura, Nagaland, Uttar Pradesh, Andhra Pradesh, Mizoram, Jammu & Kashmir, Karnataka, Telangana, Maharashtra, Goa, Madhya Pradesh, Chhattisgarh, Jharkhand, Puducherry, West Bengal, Ladakh, Himachal Pradesh, Bihar, Uttarakhand and Meghalaya.

- (ii) Total overcharged amount received during February, 2023 is Rs. 2.19 crores.

C. National Institutes of Pharmaceutical Education & Research (NIPERs):

Major Achievements of NIPERs during the month are as under:

- (a) The first meeting of the NIPER Council was held under the chairmanship of the Hon'ble Minister of Chemicals and Fertilizers on February 28, 2023.
- (b) Out of 874 Research papers published during the current financial year, 73 were published in the month of February, 2023

- (c) Out of 34 Patents filed during the current financial year, 4 were filed in the month of February, 2023
- (d) Out of 34 MoU signed during the current financial year, 8 has been signed in the month of February, 2023.
- (e) NIPER Hyderabad signed the Tripartite Memorandum of Understanding with M/o Youth Affairs and Sports and FSSAI on 15.02.2023 to establish the nutritional supplement testing capacity at the Institute.
- (f) NIPER Raebareli participated in the **UP Global Investor Summit, 2023** to showcase their achievements in research and development during February 10–12, 2023. Secretary, Department of Pharmaceuticals also visited NIPER Raebareli stall at Summit to provide support and encouragement to their faculty members, staff and students.
- (g) A one-day **international symposium** on "**Drug Discovery and Development Interface**" was organised by the Department of Pharmacology and Toxicology, NIPER Raebareli on February 1, 2023. Dr. Jitendra Sattigeri, Dr. Sachin Dubey, Dr. Seema Pai, and Mr. Bhupesh Pratap were the eminent speakers from the global pharmaceutical industries for this programme.
- (h) The **8th International Day of Women and Girls** was celebrated at NIPER Raebareli on February 11, 2023.
- (i) NIPER Raebareli celebrated **National Science Day, 2023**, on February 28, 2023, with the theme "**Global Science for Global Wellbeing**".
- (j) NIPER Raebareli organised a **workshop** entitled "**Design of Experiments and Data Analysis using JMP**" on February 23–24, 2023.
- (k) NIPER Raebareli signed the **MoU** for joint research and academic collaboration with the *CSIR-Central Drug Research Institute, Lucknow (CDRI, Lucknow)* on February 20, 2023.
- (l) NIPER Hyderabad organised a three-month student training programme on quality control and quality assurance in the pharmaceutical industry.
- (m) NIPER Hyderabad virtually signed a collaborative MoU with Taipei Medical University, Republic of China (Taiwan), on 13th February 2023. This MoU covers many aspects, like student exchange, joint programs, joint research projects, etc.
- (n) NIPER Hyderabad conducted its 10th convocation on February 24, 2023. Shri Bhagwant Khuba, the Hon'ble Minister of State for Chemicals and Fertilizers, New and Renewable Energy was the Chief Guest for this ceremony.
- (o) Avishkaran, the BioNEST of NIPER Hyderabad, organised its stall at the 20th BioAsia 2023 from February 24–26, 2023. Ms. S. Aparna, Secretary, Department of Pharmaceuticals, also visited the stall of NIPER Hyderabad.
- (p) NIPER Mohali organised a national-level industry-academic interaction entitled "**Samprabhav-2023**" on February 11 and 12, 2023.
- (q) NIPER Mohali organised the Foundation Day lecture "**Igniting Young Minds**" on February 15, 2023.
- (r) NIPER Mohali organised a guest lecture on "**Developing Sovatelide in India for Cerebral Ischemic Stroke Led to a USFDA Approval of Phase III IND**" on February 21, 2023.
- (s) NIPER Mohali organised a poster competition of Red Ribbon Clubs at the Chandigarh Group of Colleges, Landran, and Mohali on February 21, 2023.

(t) During February 20-24, 2023, NIPER Mohali hosted a one-week HPLC Training Program.

(u) NIPER Mohali celebrated National Science Day on February 28, 2023.

D. Schemes:

(i) Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):

Number of PMBJP Kendras functional		Sales under PMBJP at MRP Value in Rs. Crore and saving to common man during the month of February, 2023		Product basket (As on 28.02.2023)		Sale of Suvidha Sanitary Napkins @ Rs. 1/- per pad during the month February, 2023	Incentive provided in the month February, 2023
February 2023	Cumulative	Sale	Saving	Medicines	Surgical		
	(As on 28.02.2023)	In Rs. (Cr.)	In Rs. (Cr.) (Approx.)				
100	9182	123.62	742	1759	280	1.45 Cr.	0.76 Cr.

(ii) Status of PLI Schemes:

S. No.	Name of Scheme		Total No. of Application Received*	No. of Applications approved in the month of February 2023	Total no. of applications approved as on date
1.	Production Linked Incentive Scheme for Bulk Drug (Last EC Meeting held on 10.01.2023 on PLI Bulk Drugs)	Round 1	215	0	39
		Round 2	24	0	08
		Round 3	09	00	03
		Round 4	01	01	01
		Total	249	01	51
2.	Production Linked Incentive Scheme for Medical Device (Last EC Meeting held on 10.01.2023 on Medical Devices)	Round 1	28	0	13
		Round 2	14	0	08
		Round 3	18	05	05
		Total	60	05	26
3	Production Linked Incentive Scheme for Pharmaceuticals		278	N/A	55

E. International Cooperation:

(i) Secretary, Pharmaceuticals met with the delegation from UAE on 13.02.2023. The UAE delegation, with representatives from pharma industry, was led by H.E. Dr Amin Al Amiri, Assistant Under Secretary in Ministry of Health, UAE. The delegation was apprised of the investment opportunities in 3 bulk drug parks and 4 medical devices parks approved and supported by Government of India. Further, challenges of Indian companies exporting to UAE in obtaining time-bound marketing authorisation under India-UAE CEPA, possible collaboration with NIPERs and investment opportunities in Pharma and Medical Devices sector in UAE were also discussed.

(ii) DoP participated in the Quad Health Security Partnership meeting between Republic of India, Australia, Japan and USA on Vaccine and Health Security held on 16.02.2023 through virtual mode.

(iii) DoP participated in the 1st Joint Working Group (JWG) meeting between Republic of India and Oman on cooperation in the field of Health held on 24.02.2023 at New Delhi, wherein potential areas to strengthen bilateral cooperation in pharmaceuticals was discussed.

(iv) A workshop was organized by Department of Pharmaceuticals and Ministry of External Affairs on 24.02.2023 with select resident Missions of Asia, Africa, Latin America etc., to showcase Pradhan Mantri Bhartiya Janaushadhi Pariyojna (PMBJP) model as a best practice which can be emulated by other governments to provide quality medicines to their citizens while saving substantial amount to the public exchequer.

(v) DoP participated in the investment roadshow in Tokyo and Osaka, Japan led by Secretary, DPIIT during 27 February to 1 March 2023. The Department participated in the Make in India Seminar showcasing opportunities in Indian Pharmaceutical and Medical Devices Sector. Further, a dedicated Round Table meeting in Medical Devices was held with Japanese Companies to inform them about the investment prospects in India, encourage their greater participation in this sector and elicit information on about plans of Japanese companies w.r.t. expansion in India.

F. FDI inflow approved during this month: NIL

2. Important policy matters held up on account of prolonged inter-ministerial consultations:

NIL

3. No. of cases of 'sanction for prosecution' pending for more than three months:

NIL

4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:

NIL

5. Status of ongoing Swachhata Abhiyan (progress under Special Campaign):

The requirement of monthly updation of the SCDPM Portal for the month of February, 2023 has been fulfilled by uploading the information received from various Sections of this Department in the 2.0 version of the SCDPM Portal.

6. Status of Rationalization of Autonomous Bodies:
Completed

7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:

NIL

8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:

(i) Department of Pharmaceuticals:

S. No.	Name of the posts	Sanctioned Strength	In-position	Vacancy	Group
1	Director/DS	06	05	01	A
2	Under Secretary	10	09	01	A
3	Principal Private Secretary	02	0	02	A
4	Section Officer	16	03	13	B
	Total	34	17	17	

(ii) Public Sector Undertakings:

(a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):

S. No.	Designation	Vacant Positions
1	Senior Manager	05
2	Deputy General Manager	03
3	General Manager	06
	Total	14

(b) Hindustan Antibiotics Limited (HAL) (under strategic sale):

S.No.	Designation	Vacant Positions
1	Manager	5
2	Officer	3
3	Asstt. Officer	1
	Total	9

(c) Bengal Chemicals & Pharmaceuticals Limited (BCPL)(under strategic sale):

S.No.	Designation	Vacant Positions
1	Manager (Legal)	1
2	DGM (Marketing)	1
3	Sr. Manager (Purchase)	1
4	DGM (Finance)	1
5	Assistant Manager (Company Secretary)	1
6	Factory Head (DGM/AGM)	2
7	AGM (QA/QC)	1
	Total	8

(d) Indian Drugs & Pharmaceuticals Limited (IDPL) : NIL

(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL) : NIL

9. List of cases in which ACC directions have not been complied with:
NIL

10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:

(i)	Pending at beginning of the month	:	(3)
(ii)	Received during the month	:	(8)
(iii)	Disposed of during the month	:	(0)
(iv)	Pending at end of the month	:	(11)
